PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
G&A reduction while GNPX shows 52.68% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses change of 1234.83% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
115.67%
Operating expenses growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
115.67%
Total costs growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
719.71%
Interest expense change of 719.71% while GNPX maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Other expenses growth above 1.5x GNPX's 46.73%. Michael Burry would check for concerning trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense change of 133.51% while GNPX maintains burden. Bruce Berkowitz would investigate strategy.
-133.51%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-132.80%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.